Therapeutics

Biotechnology company developing precision genetic medicines – Beam Therapeutics (NASDAQ:BEAM) said that its CFO, Terry-Ann Burrell, will be leaving the company effective August 9, 2024. She will be pursuing a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company hasContinue Reading

aluxum United Therapeutics (NASDAQ:UTHR) traded lower on Thursday after Morgan Stanley downgraded the Tyvaso maker to Equal Weight from Overweight, citing a balanced risk-reward setup following strong gains this year. Morgan Stanley said that United Therapeutics (UTHR), which markets drugs for a lung disorder called pulmonary arterial hypertension (PAH), hasContinue Reading

Augustine Therapeutics on Wednesday announced it has raised EUR 17M ($18.5M) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company and Charcot-Marie-Tooth Research Foundation. The proceeds from this first close will be used to advance Augustine’sContinue Reading